Navigation Links
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea

-- Primary endpoint achieved --

LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA (SWX:COPN) announced today positive preliminary results from its phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) in infectious diarrhoea. CB-01-11 is a broad spectrum, semi-synthetic antibiotic that is not absorbed when taken in tablet form. Through the use of Cosmo's MMX(tm) technology, which delivers the active ingredient into the colon, bacteria in the gastro intestinal tract that are important for vitamin synthesis are not sterilized. Given that it is practically not absorbed CB-01-11 is potentially applicable for the treatment of long term infections in the colon.

In the placebo controlled, randomized, double blind trial 120 patients in 8 sites in South Africa were treated with a 200mg tablet, 4 times per day for 3 days. The trial assessed non-inferiority versus Normix® (rifaximin) and the primary endpoint was the time from first ingestion of tablet to the last unformed stool. According to the preliminary reports CB-01-11 met this primary endpoint.

Mauro Ajani, CEO of Cosmo Pharmaceuticals, commented: "We are very encouraged about these preliminary results since many of the needs of patients are not adequately met with products currently on the market. Infections of the colon affect many more persons than colon inflammations and this is consequently a substantially larger market. We believe that our proprietary MMX(tm) technology will enable us to improve a range of products in colon infections and thus better meet patients' requirements."

Further analysis of the data is ongoing.

About Cosmo Pharmaceuticals

Cosmo is a speciality pharma company that aims to become a global leader in optimised therapies for certain gastrointestinal diseases. The com­pany's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulce rative colitis and Crohn's disease, and colon infections. Cosmo's first MMX(tm) product that has reached the market is LIALDA(tm) / MEZAVANT(tm), a treatment for IBD that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX(tm) technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company's website: www.cosmopharmaceuticals.com

Contact:

Dr. Chris Tanner, CFO and Head of Investor Relations

Cosmo Pharmaceuticals SpA

Tel: +39 02 9333 7614

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

Claire Rowell Manager Financial Communications

Holborn Gate, 26 Southampton Buildings London, WC2A 1PB

T +44 (0)20 7269 7285 F +44 (0)20 7242 8695

www.fd.com

London, New York, Bahrain, Beijing, Boston, Cape Town, Chicago, Dubai, Dublin, Frankfurt, Hong Kong, Johannesburg, Manchester, Moscow, Paris, San Francisco, Stockholm and Washington.


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... Report Highlights: The report ... the investment opportunities Market forecasts till 2025, using estimated ... across the business segments, Regions and Countries Key developments ...
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute ... at high risk for acute kidney injury (AKI) ... by globally-recognized care guidelines significantly improved ... severe AKI more than 33 percent, according to ... the journal Intensive Care Medicine. ...
(Date:1/23/2017)... 23, 2017 Ahead of today,s trading session, ... they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... relative laggards on Friday, January 20 th , 2017, down on ... reports on these stocks now at: ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... services for life science companies, has achieved ISO 17100:2015 certification following a ... ISO 17100 is the globally recognized standard that establishes guidance for critical ...
(Date:1/23/2017)... ... 2017 , ... The iaedp Foundation, recognized for its excellence ... treat the full spectrum of eating disorder problems, proudly announces the addition of ... the leading eating disorder treatments centers located throughout the U.S. As partners of ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , Crystallization ... isolate and purify the desired product. Chemists now spend more time developing ...
(Date:1/23/2017)... ... ... is a set of camera tools that allow video editors to integrate up to two ... Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video editors can ... ProRandom works by using a virtual camera to create the illusion of a shaky camera. ...
Breaking Medicine News(10 mins):